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ABSTRACT
Introduction Associations between cerebral small 
vessel disease (SVD) and inflammation have been 
largely examined using peripheral blood markers of 
inflammation, with few studies measuring inflammation 
within the brain. We investigated the cross- sectional 
relationship between SVD and in vivo neuroinflammation 
using [11C]PK11195 positron emission tomography (PET) 
imaging.
Methods Forty- two participants were recruited 
(according to NIA- AA guidelines, 14 healthy controls, 
14 mild Alzheimer’s disease, 14 amyloid- positive mild 
cognitive impairment). Neuroinflammation was assessed 
using [11C]PK11195 PET imaging, a marker of microglial 
activation. To quantify SVD, we assessed white matter 
hyperintensities (WMH), enlarged perivascular spaces, 
cerebral microbleeds and lacunes. Composite scores were 
calculated for global SVD burden, and SVD subtypes 
of hypertensive arteriopathy and cerebral amyloid 
angiopathy (CAA). General linear models examined 
associations between SVD and [11C]PK11195, adjusting 
for sex, age, education, cognition, scan interval, and 
corrected for multiple comparisons via false discovery 
rate (FDR). Dominance analysis directly compared the 
relative importance of hypertensive arteriopathy and 
CAA scores as predictors of [11C]PK11195.
Results Global [11C]PK11195 binding was associated 
with SVD markers, particularly in regions typical of 
hypertensive arteriopathy: deep microbleeds (β=0.63, 
F(1,35)=35.24, p<0.001), deep WMH (β=0.59, 
t=4.91, p<0.001). In dominance analysis, hypertensive 
arteriopathy score outperformed CAA in predicting [11C]
PK11195 binding globally and in 28 out of 37 regions of 
interest, especially the medial temporal lobe (β=0.66–
0.76, t=3.90–5.58, FDR- corrected p (pFDR)=<0.001–
0.002) and orbitofrontal cortex (β=0.51–0.57, t=3.53–
4.30, pFDR=0.001–0.004).
Conclusion Microglial activation is associated with 
SVD, particularly with the hypertensive arteriopathy 
subtype of SVD. Although further research is needed to 
determine causality, our study suggests that targeting 
neuroinflammation might represent a novel therapeutic 
strategy for SVD.
INTRODUCTION
Cerebral small vessel disease (SVD) and neuroin-
flammation are increasingly recognised as key 
contributors to Alzheimer’s disease (AD) and other 
neurodegenerative disorders.1–3 Both SVD and 
neuroinflammation have been shown to promote 
neurodegeneration and worsen its clinical conse-
quences, although their pathophysiological mecha-
nisms remain unclear.3–7
Neuroinflammation plays a central role in AD 
and is increasingly recognised as an early event in 
its pathogenesis rather than a response to late stage 
disease.2 3 Under normal circumstances, inflamma-
tion acts as a natural physiological defence against 
infections and injury, thereby playing a neuroprotec-
tive role. Ordinarily, the immune response under-
goes a process of activation, whereby microglia are 
activated to combat infection, followed by reso-
lution, with microglia returning to ‘resting’ state. 
However, this process can become dysfunctional, 
such that resolution is not achieved. This results in a 
chronic state of inflammation marked by sustained 
activation of microglia, and excessive, dysregulated 
cytokine production, which can have deleterious 
effects on brain tissue, endothelial function and the 
cerebrovascular network.8
Similarly, SVD has also been associated with 
increased AD risk1 9 and can be detected on MRI in 
the form of white matter hyperintensities (WMH), 
lacunes, cerebral microbleeds (CMB) and enlarged 
perivascular spaces (EPVS).10 11 Aetiologically, these 
SVD- related brain changes are thought to be isch-
aemic in nature, resulting from arteriolar narrowing 
or occlusion. However, these arteriolar changes 
could be a late- stage phenomenon and may not 
explain early pathology potentially arising from 
other pathological processes.7 Notably, neuroin-
flammation has been recently proposed as another 
candidate mechanism that can promote or accel-
erate SVD.12
Despite the well- established role of both inflam-
mation and SVD in dementia, investigations on the 
relationship between the two mechanisms have 
been largely limited to the use of peripheral blood 
markers of inflammation (eg, C- reactive protein, 
fibrinogen),12 although some neuropathological 
evidence also exist.13 Unfortunately, peripheral 
markers may not be reflective of inflammation 
within the central nervous system (CNS) and lack 
spatial information on the distribution of neuroin-
flammation within the brain.5 As such, in vivo 
measures of neuroinflammation and topographical 
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analysis are required to further our understanding of the patho-
logical processes underlying AD and other neurodegenerative 
disorders.
In a recent systematic review, we found that serum- based 
measures of inflammation were differentially related to two 
distinct forms of SVD.12 First, markers of vascular inflamma-
tion and endothelial dysfunction were preferentially associated 
with SVD in regions typically affected by hypertensive arteri-
opathy (eg, basal ganglia). Conversely, systemic inflammatory 
markers were positively related to SVD in regions that are 
characteristically compromised in cerebral amyloid angiopathy 
(CAA) (eg, lobar microbleeds). These distinct forms of SVD 
are represented by Pantoni’s aetiological classification of type 1 
and type 2 SVD.14 Hypertensive arteriopathy is characterised by 
vascular injury in regions supplied by deep perforating arteries 
and associated with deep lacunes and microbleeds, and EPVS 
in the basal ganglia.15–18 By contrast, CAA involves vascular 
alterations in lobar/cortical regions; these regions are supplied 
by cortical and leptomeningeal vessels, which are commonly 
affected by CAA through the deposition of Aβ within these 
vessel walls.11 14 15
In this study, we examined the association between SVD and in 
vivo CNS measures of neuroinflammation using [11C]PK11195 
positron emission tomography (PET), analysing both global 
severity and regional distribution of these biomarkers. [11C]
PK11195 is a ligand of the 18 kDa translocator protein (TSPO, 
or peripheral benzodiazepine receptor) and a well- established 
PET marker of microglial activation.5 Our overarching hypoth-
esis was that neuroinflammation would be positively associated 
with SVD and that the degree of inflammation would relate to 
SVD severity. In acknowledging the different aetiologies between 
SVD subtypes, we further hypothesised that neuroinflammation 
would be more strongly related to hypertensive arteriopathy 
rather than CAA, given the stronger vascular underpinnings of 
the former (eg, hypertension, diabetes, endothelial dysfunction), 
compared with the latter, which is thought to be driven by Aβ 
deposition.14
METHODS
Forty- two participants (14 healthy controls, 14 amyloid- 
positive mild cognitive impairment (MCI), 14 early AD) above 
age 50 were recruited within the Neuroimaging of Inflamma-
tion in Memory and Other Disorders protocol (see details in 
online supplemental materials).19 MCI was defined as Mini- 
Mental State Examination (MMSE) >24, but with memory 
impairments beyond what is expected for age and education 
which did not meet the criteria for probable AD and was not 
explained by another diagnosis. Due to the heterogeneity in 
the subtypes and causes of MCI, only amyloid- positive MCI 
patients were included in this study to represent a preclinical 
stage of AD—this was defined by an average cortical 11C Pitts-
burgh Compound- B standardised uptake value ratio above 1.5. 
Probable AD was defined according to the National Institute on 
Aging- Alzheimer’s Association (NIA- AA) guidelines.20 AD and 
amyloid- positive MCI participants were combined into a single 
group on the basis that these groups represent a continuum of 
the same clinical spectrum. Healthy controls were required to 
have MMSE >26, be devoid of cognitive symptoms or unstable/
significant medical illness. Global cognition was assessed using 
the MMSE and Addenbrooke’s Cognitive Examination- Revised 
(ACE- R), and episodic memory was examined using the Rey 
Auditory Verbal Learning test.
MRI acquisition
All participants underwent 3T MRI scanning (acquisition param-
eters are detailed in online supplemental materials). T1- weighted 
images were non- rigidly registered to the ICBM2009a template 
brain using ANTS ( www. picsl. upenn. edu/ ANTS/) and inverse 
transform was applied to a modified Hammers atlas (resliced 
from MNI152 to ICBM2009a space) to bring regions of interest 
(ROI) to subject space, to which PET data described later were 
co- registered.4 6 21
PET imaging protocols
To measure the degree of neuroinflammation in the brain, all 
participants underwent [11C]PK11195 PET imaging (see acqui-
sition and processing details in online supplemental materials. 
Binding in each ROI was quantified using non- displaceable 
binding potential (BPND) determined with a simplified refer-
ence tissue model incorporating vascular binding correction and 
reference region time activity curve estimation from supervised 
cluster analysis using four kinetic classes.22 Regional BPND was 
corrected for cerebrospinal fluid contamination through division 
of the ROI time activity curve with the mean ROI fraction of 
grey matter and white matter (WM), using Statistical Parametric 
Mapping V.8 (SPM8; www. fil. ion. ucl. ac. uk/ spm/) probability 
maps smoothed to match the PET spatial resolution. Volume- 
weighted average [11C]PK11195 binding was computed for each 
individual.
Quantification of SVD
Semi-quantitative measurements
SVD markers were manually rated on structural MRI scans 
(figure 1). WMH were visually rated on fluid- attenuated inver-
sion recovery (FLAIR) MRI according to the Fazekas scale (online 
supplemental materials).23 EPVS were rated on T2- weighted 
MRI using a validated rating scale24; basal ganglia and centrum 
semiovale EPVS scores ranged from 0 to 4 according to EPVS 
count: 0 (none), 1 (1–10), 2 (11–20), 3 (21–40) and 4 (>40), 
while midbrain EPVS were rated dichotomously (present/
absent). CMB were assessed on susceptibility- weighted imaging 
following the Microbleed Anatomical Rating Scale.25 Lacunes 
were identified using T1- weighted, T2- weighted and FLAIR, 
following the STandards for ReportIng Vascular changes on 
nEuroimaging guidelines.11 Lacunes and microbleeds were clas-
sified according to location as deep (eg, basal ganglia, thalamus) 
or lobar (eg, centrum semiovale) lesions. Lacunes and CMB data 
were dichotomised separately as ‘present’ (at least one lesion) or 
‘absent’ (no lesions).
Quantitative SVD measurements
WMH volumes were obtained using an automated script on 
the SPM8 suite; details on the procedures involved have been 
described previously26 and are detailed under online supple-
mental materials. To account for individual differences in head 
size, WMH volumes were normalised by total intracranial 
volume.
Global SVD burden scores
A total SVD burden score was computed using a point system 
based on the presence or absence of each of the four SVD 
markers, according to cut- offs defined by Staals and colleagues 
(table 1).27 To examine [11C]PK11195 in relation to different 
subtypes of SVD, CAA and hypertensive arteriopathy scores 
(range 0–4 points) were formulated according to distinctions 
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made in the literature,15–18 28 assigning one point per criterion 
met (table 1; online supplemental materials).
Lesion probability mapping
To examine the spatial patterns of WMH associated with global 
[11C]PK11195 binding, we used a non- parametric permutation- 
based method implemented in FSL- PALM, adjusting for sex, age, 
education, ACE- R and scan interval between PET and MRI and 
modelling the intercept (10 000 permutations); technical details 
were previously described.29 Statistically significant clusters were 
defined using threshold- free cluster enhancement, followed by 
family- wise error rate (FWER) correction (pFWER <0.05), thus 
avoiding the need for an arbitrary cluster- forming threshold.
Statistical analysis
Statistical analysis was performed using R (https://www. r- project. 
org/). Standard statistical techniques were used for descriptive 
analyses (table 1) (see details in online supplemental materials). 
Adjusted analysis for continuous variables were conducted using 
general linear modelling. Assumptions of all linear regression 
models were first tested for skewness, heteroscedasticity and 
kurtosis and were validated to have met each linear model 
assumption. To reduce collinearity, all independent variables in 
linear models were mean- centred. All regressions were adjusted 
for the same set of covariates: sex, age, years of education, ACE- R 
score (to adjust for disease severity) and duration between MRI 
and PET scans. Given its relevance to both neuroinflammation 
and SVD, history of hypertension was included as a covariate in 
a separate step to distil its effects. To account for other vascular 
risk factors, a composite vascular risk score was computed (range 
0–4 points), whereby one point was assigned for the presence of 
each of the following: hypertension, hyperlipidaemia, diabetes 
mellitus and current smoker. This vascular risk score was also 
entered as an additional covariate in a separate regression model. 
To examine associations between global [11C]PK11195 binding 
and SVD, general linear models were constructed with [11C]
PK11195 entered as the predictor alongside the aforementioned 
covariates and SVD measures (WMH, EPVS, global SVD, hyper-
tensive arteriopathy and CAA scores) as the outcome variable 
in separate models, while analysis of covariance was performed 
to analyse [11C]PK11195 in relation to the presence/absence 
of CMB and lacunes. False discovery rate (FDR) correction 
was applied for multiple comparisons. Global SVD, hyperten-
sive arteriopathy and CAA scores were analysed in relation to 
regional binding of [11C]PK11195 across all bilateral Hammer’s 
atlas ROIs, excluding the ventricles, cerebellum and brainstem 
(37 ROIs) using general linear modelling controlling for all 
covariates and FDR- corrected. To directly compare hyperten-
sive arteriopathy and CAA on the strength of their relationship 
with [11C]PK11195, dominance analysis was conducted. Domi-
nance analysis improves on earlier methods of assessing relative 
contribution (eg, standardised coefficients, squared beta weights, 
squared zero- order correlations) due to its ability to account for 
correlations between predictors in multivariate analysis,30 an 
important feature given the potential overlap between CAA and 
hypertensive arteriopathy.
RESULTS
Participant characteristics are presented in table 2. The overall 
sample had a mean age of 71.6 (SD 8.0) years and an average 
of 13.5 (SD 3.0) years of education. Healthy controls and AD/
MCI groups were comparable on sex, age and education. As 
expected, AD/MCI participants performed significantly worse 
than healthy participants on measures of cognition (table 2). 
AD/MCI participants had greater WMH volumes than healthy 
participants, although groups were comparable on global [11C]
PK11195 binding and other SVD measures. Sixteen participants 
(43%) scored ≥2 on the CAA scale, while 8 (19%) scored ≥2 
on the hypertensive arteriopathy scale. The two SVD scales were 
positively correlated (r=0.549, p<0.001).
Figure 1 Schematic representation of multimodal imaging data, image 
processing pipeline, quantification of pathological burden and statistical 
approach to test associations between pathologies. ACE- R, Addenbrooke’s 
Cognitive Examination- Revised; cat., categorical measures, for example, 
presence/absence of microbleeds and lacunes; cov, covariates (sex, age, 
education, ACE- R, and scan interval); cont., continuous SVD measures; MLR, 
multiple linear regression; PKglobal, global [
11C]PK11195 binding; PKROI, [
11C]
PK11195 binding in each Hammer’s atlas region of interest; SVDall, each 
measure of SVD, including global and regional data of each SVD marker, 
and composite SVD scores; SVDcomp, composite SVD scores; SVD, small 
vessel disease.
Table 1 Scoring of global cerebral SVD burden, hypertensive arteriopathy and cerebral amyloid angiopathy scores
Global SVD (Staals et al)27 Hypertensive arteriopathy Cerebral amyloid angiopathy
One point per 
criterion met
WMH Periventricular WMH=3 and/or deep WMH=2 or 3 Deep WMH=2 or 3 Periventricular WMH=3 and/or deep WMH=2 or 3
EPVS EPVS rating in basal ganglia ≥2 EPVS rating in basal ganglia ≥2 EPVS rating in centrum semiovale ≥2
CMB CMB present Deep CMB present Lobar CMB present
Lacunes Lacunes present Deep lacunes present Lobar lacunes present
CMB, cerebral microbleeds; EPVS, enlarged perivascular spaces; SVD, small vessel disease; WMH, white matter hyperintensities.
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Association between whole-brain [11C]PK11195 and SVD 
markers
Whole- brain [11C]PK11195 binding was associated with total 
WMH volume in the overall sample after adjusting for age, 
sex and education and correcting for multiple comparisons 
(β=0.45, t=2.96, p=0.005). In both the overall sample and 
AD/MCI subgroup, whole- brain [11C]PK11195 binding was 
significantly associated with deep WMH (whole sample: 
β=0.59, t=4.91, p<0.001; AD/MCI: β=0.61, t=4.31, 
p<0.001), but not periventricular WMH (whole sample: 
β=0.33, t=2.01, p=0.052; AD/MCI: β=0.28, t=1.32, 
p=0.202) (figure 2A). Inclusion of hypertension or the 
composite vascular risk score into the regression model did 
not change these findings. Lesion probability maps were 
consistent with these findings, demonstrating that whole- brain 
[11C]PK11195 binding was associated with deep WMH, but 
not periventricular WMH (figure 2B).
The presence of CMB globally (whole sample: β=0.42, 
F(1,35)=10.09, p=0.003; AD/MCI: β=0.52, F(1,35)=12.16, 
p=0.002) and deep CMB (whole sample: β=0.63, 
F(1,35)=35.24, p<0.001; AD/MCI: β=0.68, F(1,35)=31.68, 
p<0.001) were associated with higher [11C]PK11195 binding in 
the whole sample and AD/MCI subgroup after correcting for 
multiple comparisons. Associations of [11C]PK11195 binding 
with lacunes and EPVS did not survive correction for multiple 
comparisons (figure 3).
Association between whole brain [11C]PK11195 and global 
SVD burden scores
Global SVD burden was associated with higher [11C]PK11195 
binding (β=0.46, t=3.31, p=0.002). In terms of SVD type, 
[11C]PK11195 was associated with both hypertensive arteriop-
athy (β=0.54, t=4.24, p<0.001) and CAA (β=0.46 t=3.25, 
p=0.003). These results were similar within the AD/MCI group, 
although only the hypertensive arteriopathy score was associ-
ated with [11C]PK11195 among healthy controls (β=0.60, 
t=3.02, p=0.019). Dominance analysis demonstrated that the 
hypertensive arteriopathy score (relative weight (RW)=0.19, 
dominance weight (DW)=0.17) significantly outperformed 
CAA (RW=0.03, DW <0.001) in predicting whole- brain [11C]
PK11195.
Association between global SVD burden scores and regional 
[11C]PK11195 distribution
ROI analysis indicated a significant relationship between 
hypertensive arteriopathy and [11C]PK11195 binding in 22 of 
the 37 Hammers atlas ROIs after FDR correction (figure 4). 
Associations with hypertensive arteriopathy score were espe-
cially robust with respect to [11C]PK11195 binding in the 
temporal lobe, particularly the medial temporal lobe (hippo-
campus: β=0.76, t=4.95, FDR- corrected p (pFDR) <0.001, 
amygdala: β=0.76, t=5.58, pFDR=0.002, parahippocampal 
and ambient gyri: β=0.66, t=3.90, pFDR <0.001), anterior 
Table 2 Participant characteristics
Healthy controls AD/MCI P value
N 14 28
Demographics
  Sex† % Female 42.9% 42.9% 1.000
  Age (years)‡ Mean (SD) 70.4 (6.4) 72.2 (8.7) 0.480
  Education (years)§ Mean (SD) 14.4 (2.8) 13.1 (3.1) 0.147
  Hypertension† % Present 21.4% 25.0% 0.798
  Hyperlipidaemia† % Present 14.3% 33.3% 0.192
  Diabetes mellitus† % Present 7.1% 7.1% 1.000
  History of smoking† % Present 50.0% 17.9% 0.030*
  Current smoker† % Present 0.0% 7.1% 0.306
Cognition
  MMSE§ Mean (SD) 28.9 (1.1) 25.3 (2.5) <0.001***
  ACE- R‡ Mean (SD) 93.5 (4.4) 77.8 (8.9) <0.001***
  RAVLT‡ Mean (SD) 44.6 (9.1) 25.0 (8.7) <0.001***
Imaging features
  WMH volume§¶ Mean (SD) 0.28 (0.26) 0.73 (0.58) 0.017*
  Whole brain(11C)PK11195‡ Mean (SD) 0.04 (0.03) 0.06 (0.05) 0.197
  EPVS (basal ganglia)†† Mean (SD) 1.43 (0.65) 1.54 (0.74) 0.678
  CMB† % Present 42.9% 32.1% 0.495
  Lacunes† % Present 42.9% 46.4% 0.826
  Global SVD score (0–4)†† Mean (SD) 1.43 (1.22) 1.79 (1.34) 0.443
  CAA score (0–4)†† Mean (SD) 1.00 (1.04) 1.57 (1.40) 0.235
  HA score (0–4)†† Mean (SD) 0.57 (0.85) 0.96 (1.07) 0.254
*p<0.05; ***p<0.001.
†χ2 test of independence.
‡T- test.
§Mann- Whitney U test.
¶Normalised volume adjusted for TIV: (volume in mL/TIV) × 100%.
††Kruskal- Wallis test.
ACE- R, Addenbrooke’s Cognitive Examination- Revised; AD, Alzheimer’s disease; CAA, cerebral amyloid angiopathy; CMB, cerebral microbleeds; EPVS, enlarged perivascular 
spaces; HA, hypertensive arteriopathy; MCI, mild cognitive impairment; MMSE, Mini- Mental State Examination (amyloid- positive); RAVLT, Rey Auditory Verbal Learning Test; SVD, 
small vessel disease; TIV, total intracranial volume; WMH, white matter hyperintensities.
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temporal lobe (β=0.59–0.63, t=3.53–3.93, pFDR=0.002–
0.004) and the orbitofrontal cortex (β=0.51–0.57, t=3.53–
4.30, pFDR=0.001–0.004).
CAA was related to higher [11C]PK11195 binding in 13 
ROIs. The majority of these ROIs were a subset of hyperten-
sive arteriopathy- related ROIs, including the temporal lobe 
(β=0.27–0.54, t=1.42–3.60, pFDR=0.017–0.205) and antero-
medial orbitofrontal cortex (β=0.40–0.44, t=2.70–3.10, 
pFDR=0.027–0.033). CAA was related to some medial temporal 
lobe structures, but notably to a weaker extent (hippocampus: 
β=0.45, t=2.75, pFDR=0.032, amygdala: β=0.49, t=2.76, 
pFDR=0.032, parahippocampal and ambient gyri: β=0.27, 
t=1.42, pFDR=0.205(ns)) than in hypertensive arteriopathy. A 
structure in which [11C]PK11195 was uniquely associated with 
CAA, but not hypertensive arteriopathy, was the anterior cingu-
late (β=0.41, t=2.77, pFDR=0.032).
Dominance analysis was used to compare the relative impor-
tance of hypertensive arteriopathy and CAA scores as predictors 
of [11C]PK11195 binding in each ROI. The hypertensive arte-
riopathy score outperformed CAA in predicting [11C]PK11195 
binding in 28 out of the 37 ROIs, while CAA did not dominate 
in any ROI. In line with the independent ROI analyses earlier, 
the greatest degree of hypertensive arteriopathy dominance over 
CAA was observed in the medial temporal lobe (hypertensive 
arteriopathy DW=0.25–0.26; CAA DW≤0.001–0.05) and orbi-
tofrontal cortex (hypertensive arteriopathy DW=0.21–0.26; 
CAA DW=0.02–0.10). Regions in which neither SVD subtype 
dominated include the cingulate gyrus (anterior and posterior), 
subcallosal area and basal ganglia structures (nucleus accumbens, 
putamen and pallidum).
DISCUSSION
We found positive associations between in vivo neuroinflamma-
tion (microglia activation) and markers of SVD, particularly with 
the hypertensive subtype of SVD rather than CAA. Hypertensive 
arteriopathy outperformed CAA as a predictor of whole- brain 
[11C]PK11195 binding and across many ROI, especially the 
medial temporal lobe and orbitofrontal cortex.
The relationship between cerebral SVD and inflammation has 
been largely examined using peripheral blood markers of inflam-
mation,12 which lack topological specificity to detect inflamma-
tion in the brain. As such, the present study expands on existing 
literature by examining topographical associations between 
neuroinflammation and different markers of SVD (WMH, EPVS, 
microbleeds, lacunes). Elevated neuroinflammation was asso-
ciated with greater WMH and microbleed burden, while rela-
tionships with EPVS and lacunes were non- significant. Notably, 
the link between neuroinflammation and SVD was present only 
in AD/MCI patients, but not controls. This suggests that the 
interaction between SVD and neuroinflammation might have a 
key pathogenetic role in neurodegeneration rather than simply 
reflecting an age- related effect. Nevertheless, we acknowledge 
that our sample size was limited, and further studies are needed 
to confirm the interplay between SVD, neuroinflammation and 
neurodegeneration.
While the presence and directionality of causal mechanisms 
cannot be determined from this cross- sectional study, animal 
studies suggest that inflammation precedes, and may be caus-
ally related to, SVD.12 31 32 This is demonstrated especially by 
Figure 2 Association between whole brain [11C]PK11195 binding and 
WMH. (A) Scatterplot of whole brain [11C]PK11195 binding with WMH 
volumes. WMH values are residuals adjusted for sex, age, education, 
ACE- R score and scan interval. (B) Lesion probability maps of [11C]
PK11195- related WMH spatial distribution, adjusted for sex, age, 
education, ACE- R score and scan interval. ACE- R, Addenbrooke’s Cognitive 
Examination- Revised; AD, Alzheimer’s disease; FWE, family- wise error; 
HC, healthy controls; MCI, mild cognitive impairment; WMH, white matter 
hyperintensities.
Figure 3 Graphical summary of associations between global [11C]
PK11195 and SVD across imaging markers and regions. Values represent 
standardised beta coefficients of the individual markers, adjusted for 
sex, age, education, ACE- R and scan interval. Multiple linear regression 
was conducted for WMH and EPVS, while ANCOVA was conducted for 
presence/absence of CMB and lacunes. Colour scale represents p values, 
whereby darker shades signify smaller p values and unshaded (white) cells 
are not statistically significant. *p<0.05, **p<0.01, ***p<0.001; bold 
values represent statistical significance (p<0.05) before correcting for 
multiple comparisons; underlined values represent statistical significance 
(p<0.05) after false discovery rate correction for multiple comparisons 
(12 measures × 3 groups=36 comparisons). ACE- R, Addenbrooke’s 
Cognitive Examination- Revised; ANCOVA, analysis of covariance; AD/MCI, 
participants with Alzheimer’s disease or mild cognitive impairment; BG, 
basal ganglia; CMB,cerebral microbleeds; CSO, centrum semiovale; DWMH, 
deep white matter hyperintensities; HC, healthy controls; EPVS, enlarged 
perivascular spaces; MLR, multiple linear regression; PVH, periventricular 
white matter hyperintensities; MB, midbrain; SVD, small vessel disease; 
WMH, white matter hyperintensities.
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the reversal of WM damage observed following the use of drugs 
targeting inflammation and the endothelium, as well as the iden-
tification of a single- nucleotide polymorphism of a gene in SVD 
patients, a gene responsible for endothelial dysfunction when 
mutated in rats.31 32
The relationship between [11C]PK11195 binding and SVD 
was more pronounced in hypertensive arteriopathy (rather than 
CAA). This differential association of neuroinflammation specif-
ically with hypertensive arteriopathy implies that SVD subtypes 
involve distinct pathophysiological aetiologies and could shed 
light on the mechanisms linking inflammation and SVD. While 
CAA results from β- deposition in vessel walls, hypertensive 
SVD has stronger vascular involvements, implicating hyper-
tension, blood pressure and leakages of the blood brain barrier 
(BBB).14 Hypertensive arteriopathy is characterised by lesions 
in deep subcortical regions like the basal ganglia. Anatomically, 
these areas are supplied by deep perforating arteries suscep-
tible to twisting/looping and luminal narrowing, which can 
be exacerbated by hypertension. Inflammation is thought to 
promote vessel occlusion and endothelial dysfunction leading to 
increased BBB permeability—this in turn increases vessel wall 
fragility, which has been suggested to result in vessel ruptures 
and ‘leakage’ of red blood cells into the parenchyma, that is, 
microbleeds.33 In turn, the increased BBB permeability itself 
may also lead to a persistent immune response and a chronic 
neuroinflammatory state, resulting in a vicious cycle of patho-
logical processes (figure 5). Taken altogether, neuroinflamma-
tion appears to be an early event in SVD. Although the precise 
sequence of events remains a topic of debate, evidence implicates 
neuroinflammation in the cascade of processes leading ultimately 
to the brain alterations seen in SVD.
Contrary to other SVD markers, neuroinflammation was 
related to EPVS in the centrum semiovale (CAA- related), rather 
than the basal ganglia (hypertension- related). This is perhaps 
unsurprising, given that EPVS itself has been considered a 
marker of neuroinflammation.34 Perivascular spaces are direct 
conduits for the drainage of interstitial fluids, making them 
vulnerable as a gateway for harmful foreign antigens to enter the 
brain. These foreign antigens, including inflammatory stimuli, 
lead to small vessel alterations and perivascular oedema. When 
these perivascular structures are compromised, manifested as 
MRI- visible EPVS, they are also proposed to be early markers of 
BBB dysfunction.35
Regional analysis showed that hypertensive arteriopathy was 
associated with widespread neuroinflammation, particularly in 
the medial temporal lobe (eg, hippocampus) and orbitofrontal 
cortex (including basal forebrain). CAA- related neuroinflam-
mation was less widespread but overlapped with some regions 
of hypertensive arteriopathy- related inflammation such as 
the temporal lobe and basal forebrain. Notably, CAA was not 
related to hippocampal neuroinflammation which was robustly 
associated with hypertensive SVD. The exclusive involvement of 
hypertensive SVD in hippocampal inflammation may perhaps 
be attributed to the hippocampus’ (1) heightened sensitivity to 
vascular alterations resulting from its unique vascular architec-
ture and perfusion characteristics36 and/or (2) significance as the 
earliest region to lose BBB integrity.37
Although CAA and hypertensive arteriopathy have been 
discussed as distinct SVD subtypes thus far, overlaps in pathology 
may exist, with suggestions that hypertensive arteriopathy may 
initiate and speed up the development of CAA and amyloid β 
accumulation.38
This study has implications on clinical decision- making and 
future research directions. In both clinical and research settings, 
SVD is commonly treated as a homogeneous construct. However, 
our present findings suggest different aetiological processes 
underlying two distinct forms of SVD, whereby neuroinflam-
mation is implicated in hypertensive SVD more so than CAA. 
This provides a basis for clinicians and scientists to distinguish 
between the two SVD subtypes and better characterise their 
pathophysiological differences. Clinically, recognising the differ-
ential mechanisms behind the two forms of SVD would be partic-
ularly relevant for treatment decisions. One recent animal study 
demonstrated that microglial depletion prevented BBB leakage 
and hypertension- related cognitive impairment,39 although it is 
unclear whether the success of such interventions would extend 
to CAA- type SVD.
Figure 4 Associations between regional [11C]PK11195 binding 
and hypertensive arteriopathy (n=42). (A) β- weight brain mapping of 
associations between regional [11C]PK11195 binding and hypertensive 
arteriopathy. Coloured overlay of the Hammers atlas represents statistically 
significant elevation of [11C]PK11195 binding with hypertensive 
arteriopathy score controlling for sex, age, education, ACE- R score and 
scan interval and corrected for multiple comparisons. Colour gradient 
represents the strength of association (standardised β weights), increasing 
in magnitude from light blue to fuchsia. (B) Scatterplots of relationships 
between hypertensive arteriopathy (y- axis) and [11C]PK11195 binding 
in key regions of interest (x- axis). Hypertensive arteriopathy values are 
residuals, adjusted for sex, age, education, ACE- R and scan interval. ACE- R, 
Addenbrooke’s Cognitive Examination- Revised; SVD, small vessel disease.
Figure 5 The vicious cycle of neuroinflammation and cerebral small 
vessel disease.
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A strength of this study is the in vivo measurement of neuroin-
flammation using PET imaging of [11C]PK11195, which is an 
improvement over peripheral inflammatory markers given its 
ability to provide CNS neuroinflammatory measures and spatial 
information. Another key strength involves the comprehensive 
characterisation of SVD—all four major MRI markers of SVD 
were included, and region- specific burden was quantified for 
each SVD marker. In addition to global SVD burden,27 regional 
SVD measures allowed us to compute composite scores to 
examine different forms of SVD. Study limitations include its 
cross- sectional design, a relatively small sample size and inherent 
shortcomings of the [11C]PK11195 tracer such as low signal- to- 
noise TSPO binding. While further research should be conducted 
longitudinally on larger sample sizes using second- generation 
TSPO tracers such as [11C]PBR28, the use of [11C]PK11195 has 
its advantages, such as its selectivity for activated microglia over 
quiescent microglia and reactive astrocytes, its relative insensi-
tivity to common TSPO polymorphisms compared with second- 
generation tracers and its well- established methods for kinetic 
analysis.4 5 40 To examine the directionality of their relationship, 
Mendelian randomisation could be used to investigate the effects 
of genetic variants associated with inflammation on SVD.
To the best of our knowledge, this study presents the first 
investigation on SVD and in vivo neuroinflammation (microg-
lial activation) using [11C]PK11195 PET imaging. Our findings 
indicate associations between microglial activation and SVD, 
especially in hypertensive SVD. Further investigations (eg, longi-
tudinal studies) are needed to establish the causal nature of the 
relationship observed, but our results suggest that targeting 
neuroinflammation might represent a potential novel thera-
peutic pathway in treating SVD.
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